The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis
Abstract
A randomised, double-blind, phase II, dose escalation trial was conducted to assess the safety, tolerability and pharmacokinetics of the tyrosine kinase inhibitor nintedanib, alone and when added to ongoing pirfenidone therapy, in Japanese patients with idiopathic pulmonary fibrosis. 50 Japanese patients were randomised to receive nintedanib or placebo in one of three cohorts (nintedanib 50 mg twice daily or 100 mg twice daily for 14 days, or 150 mg twice daily for 28 days). Patients receiving pirfenidone at inclusion were stratified to every nintedanib dose group and placebo. Adverse events were reported in nine out of 17 patients receiving nintedanib alone and 10 out of 21 patients receiving nintedanib added to pirfenidone. All adverse events were mild or moderate in intensity. Gastrointestinal disorders were the most common adverse event. Maximum plasma concentration and area under the curve at steady state for nintedanib and its metabolites tended to be lower when nintedanib was added to pirfenidone. Nintedanib had no effect on the pharmacokinetics of pirfenidone. In conclusion, further study is needed to evaluate the safety and tolerability profile of nintedanib when added to pirfenidone in patients with idiopathic pulmonary fibrosis. There was a trend toward lower exposure of nintedanib when it was added to pirfenidone.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Fibroblasts derived from eight individuals with and without IPF were exposed to ACT001, and results demonstrated decreased fibroblast activity, as measured by reduced fibroblast viability and proliferation, fibronectin expression, and fibroblast to myofibroblast transition, along with a reduction in interleukin-6 (IL-6) activity [87].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [87]
Citations
Cites
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationEfficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Self-citationA phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
Pirfenidone in idiopathic pulmonary fibrosis
Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., Taguchi, Y., Takahashi, H., Nakata, K., Sato, A., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00005209 · Cited by 946
Self-citationPirfenidone in idiopathic pulmonary fibrosis: Figure 1–
Swigris, J., & Fairclough, D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00071710 · Cited by 799
Wollin, L., Maillet, I., Quesniaux, V., Holweg, A., & Ryffel, B. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.208223 · Cited by 633
Research works printed but not linked: 1
- Pulmonary Physiology Specialist Committee of the Japanese Respiratory Society, 2001, Predicted values of spirometry and arterial blood gas analysis in Japanese, J Jpn Respir Soc, 39, 1
Cited by
Richeldi, L., Collard, H. R., & Jones, M. G. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30866-8 · Cited by 2,020
Idiopathic pulmonary fibrosis: pathogenesis and management
Sgalla, G., Iovene, B., Calvello, M., Ori, M., Varone, F., & Richeldi, L. (2018) · Respiratory Research · doi:10.1186/s12931-018-0730-2 · Cited by 573
Idiopathic Pulmonary Fibrosis (IPF): An Overview
Barratt, S., Creamer, A., Hayton, C., & Chaudhuri, N. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7080201 · Cited by 382
The role of myofibroblasts in wound healing
Hinz, B. (2016) · Current Research in Translational Medicine · doi:10.1016/j.retram.2016.09.003 · Cited by 328
Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial
Vancheri, C., Kreuter, M., Richeldi, L., Ryerson, C. J., Valeyre, D., Grutters, J. C., Wiebe, S., Stansen, W., Quaresma, M., Stowasser, S., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201706-1301oc · Cited by 305
“These were reported more commonly in the 13 patients who received nintedanib 150 mg twice daily on top of pirfenidone background therapy (in 4 and 5 patients, respectively) compared with the 11 patients who received nintedanib 150 mg twice daily only (in 1 and no patients, respectively) (11).”
BackgroundMethodResultInfluential
Metadata
- Authors
- Ogura, T., Taniguchi, H., Azuma, A., Inoue, Y., Kondoh, Y., Hasegawa, Y., Bando, M., Abe, S., Mochizuki, Y., Chida, K., Klüglich, M., Fujimoto, T., Okazaki, K., Tadayasu, Y., Sakamoto, W., & Sugiyama, Y.
- Affiliations
- Kanagawa Cardiovascular and Respiratory Center (JP)
- Tosei General Hospital (JP)
- Nippon Medical School (JP)
- NHO Kinki Chuo Chest Medical Center (JP)
- Nagoya University (JP)
- Jichi Medical University (JP)
- Himeji Medical Center (JP)
- Hamamatsu University School of Medicine (JP)
- Boehringer Ingelheim (Germany) (DE)
- Boehringer Ingelheim (Japan) (JP)
- ORCID
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2014-12-10
- Volume
- 45
- Issue
- 5
- Pages
- 1382-1392
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2146127863
- Cited by
- 215
- References
- 18
- Citations by year
- 2026: 6 · 2025: 8 · 2024: 16 · 2023: 16 · 2022: 16 · 2021: 18 · 2020: 18 · 2019: 18 · 2018: 27 · 2017: 28 · 2016: 21 · 2015: 22
- FWCI
- 18.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Respiratory Journal (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Boehringer Ingelheim
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, pirfenidone, idiopathic pulmonary fibrosis, tyrosine kinase inhibitors, pharmacokinetics, drug safety and tolerability, adverse events, gastrointestinal adverse effects, drug-drug interactions, Japanese patients
- MeSH terms
- Aged, Anti-Inflammatory Agents, Non-Steroidal, Dose-Response Relationship, Drug, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Japan, Male, Middle Aged, Pyridones, Vital Capacity, Treatment Outcome, Idiopathic Pulmonary Fibrosis, Patient Safety
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. https://app.cochat.ai/papers/10.1183/09031936.00198013
- The paper
- Ogura, T., Taniguchi, H., Azuma, A., Inoue, Y., Kondoh, Y., Hasegawa, Y., Bando, M., Abe, S., Mochizuki, Y., Chida, K., Klüglich, M., Fujimoto, T., Okazaki, K., Tadayasu, Y., Sakamoto, W., & Sugiyama, Y. (2015). Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. European Respiratory Journal. https://doi.org/10.1183/09031936.00198013
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.